Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech gmasson Mon, 11/11/2024 - 15:19.: Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two antibody-drug conjugates (ADCs). Healthcare investor OrbiMed led the oversubscribed series D financing, with Novo Nordisk’s asset manager Novo Holdings and Jeito Capital co-leading the round, according to a Nov. 12 release. RA Capital Management, Frazier Life Sciences, Longitude Capital, Catalio Capital and Morningside Venture Investments also participated, among others. Alentis will use the money to advance a pipeline of medicines targeting Claudin-1 (CLDN1).